Antimicrobial blood concentrations in burns. A five years retrospective survey.;Concentrations sanguines d'antibiotiques chez les patients brûlés. Étude rétrospective sur cinq ans

Pathologie Biologie

Volumn 58, Issue 2, 2010, Pages 137-143

  Le Floch, R ^a   Arnould, J F ^a   Pilorget, A ^a   Dally, E ^a   Naux, E ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Antimicrobials; Blood concentration; Burns; Regimen

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; CLOXACILLIN; GENTAMICIN; IMIPENEM; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; VANCOMYCIN;

ADOLESCENT; ADULT; ARTICLE; BURN; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; RETROSPECTIVE STUDY; STEADY STATE;

EID: 77952428014     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2009.07.030     Document Type: Article

References (39)

1. Richard P., Le Floch R., Chamoux C. Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains. J Infect Dis 1994, 170(2):377-383.
2. Dell'Aquila A., Mc Culloch J., Mamizuka E., Santos S.R., Pereira C.A. Serum levels of vancomycin should be monitored in burn patients. Burns 2004, 30:386-387.
3. Potel G., Caillon J., Jacqueline C., Navas D., Kergueris M.F., Batard E. Dosage des antibiotiques en réanimation: quand et comment demander et interpréter les tests ?. Reanimation 2006, 15:187-192.
4. Garraffo R., Lavrut T. Signification clinique des corrélations pharmacocinétique/pharmacodynamie des antibiotiques chez les patients de réanimation. Reanimation 2005, 14:264-275.
5. Moore R.D., Lietman P.S., Smith C.R. Clinical response to aminoglycoside therapy: importance of the peak concentration to minimal inhibitory concentration. J Infect Dis 1987, 155:93-99.
6. Jaehde U., Sorgel F. Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet 1995, 29(1):15-28.
7. Saivin S., Conil J.M., Houin G. Les perturbations générales de la pharmacocinétique des médicaments chez le sujet brûlé. Brulures 2000, 1(3):145-154.
8. Lesne-Hulin A., Bourget P., Carsin H. Pharmacocinétique des antibiotiques chez les brûlés. Therapie 1995, 50:575-586.
9. Weinbren M. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 1999, 44:319-327.
10. Boucher B.A., Kuhl D.A., Hickerson W.L. Pharmacokinetics of systematically administered antibiotics in patients with thermal injury. Clin Infect Dis 1992, 14(2):458-463.
11. Pea F., Viale P., Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005, 44(10):1009-1034.
12. Lovering A.M., Le Floch R., Hovsepian L?, Stephanazzi J., Bret P., Birraux G., et al. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother 2009, 63:553-559.
13. Carlet J., Tabah A. Antibiotic therapy in serious infectious states. Med Mal Infect 2006, 36:299-303.
14. Syposs T., Csiba A., Novak J., Gráber H., Firr M. Serum level of antibiotics in burn patients. Zentralbl Chir 1986, 111(24):1519-1525.
15. Mehrotra R., De Gaudio R., Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004, 30(12):2145-2156.
16. Frimodt-Moller N. How predictive is PK/PD for antimicrobial agents?. Int J Antimicrob Agents 2002, 19:333-339.
17. Martin J., Mendez R., Alemany T. Studies on clavulanic acid. Part 1. Stability of clavulanic acid in solutions of amines containing hydroxy groups. J Chem Soc [Perkin 2] 1989, 223-226.
18. Conil J.M., Georges B., Lavit M., Seguin T., Tack I., Samii K. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance. Int J Pharmacol Ther 2007, 45(10):529-538.
19. Rio Y, Leroy F, Humbert G, Didion J. Comparative ceftazidime serum concentrations during continuous infusion in healthy subjects and severe burn patients. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994 (Abstract A 13).
20. Miyagawa C., Andrle A., Healy D. Continuous ceftazidime infusions in critically ill surgical patients. J Infect Dis Pharm 1999, 4(1):25-34.
21. Nicolau D., Lacy M., Mc Nabb, Quintiliani R., Nightingale C.H. Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia. Infect Dis Clin Pract 1999, 8:45-49.
22. Lipman J., Gomersall C., Gin T., Joynt G.M., Young R.J. Continuous infusion ceftazidime in intensive care. A randomised controlled trial. J Antimicrob Chemother 1999, 43:309-311.
23. Viaene E., Chanteux H., Servais H., Mingeot-Leclercq M.P., Tulkens P.M. Comparative stability of antipseudomonal agents administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor operated syringes (intensive care units). Antimicrob Agents Chemother 2002, 46(8):2327-2332.
24. Chevrolet J.C., Tassaux D., Jolliet P., Pugin J. Syndrome de détresse respiratoire aiguë. EMC pneumologie 2004, 1:143-186.
25. Leder K., Turnidge J., Korman T., Grayson M.L. The clinical efficacy of continuous - infusion flucloxacillin in serious staphylococcal sepsis. J Antimicrob Chemother 1999, 43:113-118.
26. Moore R., Lietman P., Smith C. Clinical response to aminoglycoside therapy: the importance of the ratio peak concentration to minimal inhibitory concentration. J Infect Dis 1987, 155(1):93-99.
27. Maller R., Issackson B., Nilson L., Sörén L. A study of amikacin given once (versus twice) daily in serious infection. J Antimicrob Chemother 1988, 22(1):75-79.
28. Marik P.E., Lipman J., Kobilski S., Scribante J. A prospective randomized study comparing once (versus twice) daily amikacine dosing in critically ill adults and paediatric patients. J Antimicrob Chemother 1991, 28(5):753-764.
29. Société française d'anesthésie et de réanimation. Antibiothérapie probabiliste des états septiques graves. Ann Fr Anesth Reanim 2004;23:1020-6.
30. Zaske D., Sawchuck R., Gerding D., Strate R.G. Increased dosage requirements of gentamicin in burn patients. J Trauma 1976, 16(10):824-828.
31. Arnould JF, Le Floch R. Aminosides: la pharmacocinétique, la pharmacodynamie et la vraie vie. Société française d'étude et de traitement des brûlures, XXV congrès, Lille, 2005 (Abstract 3).
32. Zaske D., Sawchuck R., Strate R. The necessity of increased doses of amikacin in burn patients. Surgery 1978, 84(5):603-608.
33. Conil J.M., Georges B., Brenden A., Segonds C., Lavit M., Seguin T., et al. Increased amikacin dosage requirements in burn patients receiving a once - daily regimen. Int J Antimicrob Agents 2006, 28(3):226-230.
34. Hoey L.L., Tschida S.J., Rotschafer J.C., Guay D.R.P., Vance-Bryan K. Wide variations in single, daily - dose aminoglycoside pharmacokinetics in patients with burn injuries. J Burn Care Rehabil 1997, 18(2):116-124.
35. Drusano G., Preston S., Fowler C., Corrado M., Weisinger B., Kahn J. Relationship between fluoroquinolones area under curve: minimum inhibitory concentration ratio and the probability of eradication of the infection pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004, 189(9):1590-1597.
36. Garrelts J., Jost G., Kowalsky S.F., Krol G.J., Lettieri J.T. Ciprofloxacin pharmacokinetics in burn patients. Antimicrob Agents Chemother 1996, 40(5):1153-1156.
37. Lesne-Hulin A., Bourget P., Ravat F., Goudin C., Latarjet J. Clinical pharmacokinetics of ciprofloxacin in patients with major burns. Eur J Clin Pharmacol 1999, 55(7):515-519.
38. Wysocki M., Delatour F., Faurisson F., Rauss A., Pean Y., Misset B., et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized trial. Antimicrob Agents Chemother 2001, 45(9):2460-2467.
39. Conil J.M., Favarel H., Laguerre J., Brouchet A., Chabanon G., Cazal L., et al. Continuous administration of vancomycin in patients with severe burns. Presse Med 1994, 23(34):1554-1558.